SUPPORT-pVAD

Multicenter randomized crossover trial to evaluate the prompt hemodynamic effect of inhaled nitric oxide in cardiogenic shock patients with percutaneous ventricular assist device - SUPPORT-pVAD

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1061230015

Enrollment

Registered

2023-05-20

Start date

2025-03-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiogenic shock Cardiogenic shock

Interventions

Inhaled nitric oxide (20ppm 10min, 40ppm 5min)

D009569

Inhaled nitric oxide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. 18 years-old or older 2. Signed and dated written informed consent 3. Cardiogenic shock 4. Supported with Impella 5.5, Impella CP 5. Indwelled with Pulmonary artery catheter

Exclusion criteria

Exclusion criteria: 1. Using other mechanical circulatory support device except Impella 5.5 and Impella CP 2. Using nitroprusside, nitroglycerin, or sulfonamide 3. Pregnant or breastfeeding 4. Dependent on right to left shunt 5. Allergy to nitric oxide 6. Systolic blood pressure less than 90 mmHg 7. Judged as inappropriate by researchers

Design outcomes

Primary

Measure	Time frame
Change of cardiac index ( LaFarge-Miettien fomula) from baseline to 15 minutes after intervention.	—

Secondary

Measure	Time frame
1. change of mean pulmonary artery pressure 2. change of pulmonary vascular resistance 3. change of cardiac power output	—

Contacts

Public ContactIwasaki Keiichiro

Okayama University Hospital

p8w24uzd@s.okayama-u.ac.jp+81-86-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026